Drugs.com - Clinical Trials

GRIN Therapeutics Receives FDA Orphan Drug Designation for Radiprodil for the Treatment of GRIN-Related Neurodevelopmental Disorder

NEW YORK, NY, March 17, 2025– GRIN Therapeutics, Inc., a leader in the development of therapies to treat serious neurodevelopmental disorders, today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug designation for...

Mar 19, 2025 - 21:27
 0
GRIN Therapeutics Receives FDA Orphan Drug Designation for Radiprodil for the Treatment of GRIN-Related Neurodevelopmental Disorder
NEW YORK, NY, March 17, 2025– GRIN Therapeutics, Inc., a leader in the development of therapies to treat serious neurodevelopmental disorders, today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug designation for...
Read More

Tags:

Previous Article

Signal12 Achieves FDA Alignment, Accelerating Pro-ocular™ Towards Phase 3 Clinic...

Next Article

Derby breaks ground on park expansion, considers zoning for senior project

Related Posts

Investigational Rinatabart Sesutecan (Rina-S®) Continues to Show Encouraging Antitumor Activity in Patients with Advanced Ovarian Cancer

Investigational Rinatabart Sesutecan (Rina-S®) Continue...

Mar 19, 2025  0

Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa

Denali Therapeutics Announces Primary Analysis and Long...

Mar 7, 2025  0

Lundbeck’s Potential Treatment Amlenetug for Multiple System Atrophy Receives Fast Track Designation From the FDA

Lundbeck’s Potential Treatment Amlenetug for Multiple S...

Feb 17, 2025  0